[go: up one dir, main page]

AU2001294373A1 - Differentially expressed epitopes and uses thereof - Google Patents

Differentially expressed epitopes and uses thereof

Info

Publication number
AU2001294373A1
AU2001294373A1 AU2001294373A AU9437301A AU2001294373A1 AU 2001294373 A1 AU2001294373 A1 AU 2001294373A1 AU 2001294373 A AU2001294373 A AU 2001294373A AU 9437301 A AU9437301 A AU 9437301A AU 2001294373 A1 AU2001294373 A1 AU 2001294373A1
Authority
AU
Australia
Prior art keywords
cells
cell
binding
binding molecule
diseased cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294373A
Other languages
English (en)
Inventor
Andries Christiaan Bloem
Lucia Cilenti
Ton Logtenberg
Renate Marie Louise Zwijssen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of AU2001294373A1 publication Critical patent/AU2001294373A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Magnetic Record Carriers (AREA)
AU2001294373A 2000-08-28 2001-08-27 Differentially expressed epitopes and uses thereof Abandoned AU2001294373A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22842900P 2000-08-28 2000-08-28
US60228429 2000-08-28
EP00202991 2000-08-28
EP00202991A EP1184458A1 (fr) 2000-08-28 2000-08-28 Epitopes de CD46 exprimés différentiellement, des molécules protéiniques capables de s'y lier, et leurs utilisations
PCT/NL2001/000636 WO2002018948A2 (fr) 2000-08-28 2001-08-27 Epitopes exprimes de maniere differentielle et utilisations associees

Publications (1)

Publication Number Publication Date
AU2001294373A1 true AU2001294373A1 (en) 2002-03-13

Family

ID=8171959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294373A Abandoned AU2001294373A1 (en) 2000-08-28 2001-08-27 Differentially expressed epitopes and uses thereof

Country Status (4)

Country Link
EP (2) EP1184458A1 (fr)
AU (1) AU2001294373A1 (fr)
CA (1) CA2420276A1 (fr)
WO (1) WO2002018948A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
ATE524196T1 (de) * 2001-10-16 2011-09-15 Macrogenics West Inc An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
EP2395017A3 (fr) 2003-05-30 2012-12-19 Merus B.V. Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1737971B1 (fr) 2004-01-20 2017-08-16 Merus N.V. Mélanges de proteines de liason
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CN103476429B (zh) * 2010-09-03 2016-08-24 施特姆森特克斯股份有限公司 新型调节剂及使用方法
WO2012031280A2 (fr) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification et enrichissement de sous-populations cellulaires
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
EP3191524A4 (fr) 2014-09-12 2018-05-30 The Regents of The University of California Anticorps anti-cd46 humains formant des macropinosomes et agents thérapeutiques anti-cancéreux ciblés
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2018089829A1 (fr) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cellules effectrices spécifiques de cd46 et leurs utilisations
KR20230066149A (ko) 2020-08-07 2023-05-12 포티스 테라퓨틱스, 인크. Cd46을 표적화하는 면역접합체 및 이의 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133111D1 (de) * 1990-05-11 2002-10-24 Austin Res Inst Heidelberg CD46 Isoformen
JPH0445796A (ja) * 1990-06-08 1992-02-14 Kyowa Hakko Kogyo Co Ltd 抗ｍｃｐモノクローナル抗体
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU6150498A (en) * 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
AU8755798A (en) * 1997-04-04 1998-11-13 Biosite Diagnostics Incorporated Polyvalent and polyclonal libraries

Also Published As

Publication number Publication date
CA2420276A1 (fr) 2002-03-07
EP1356285A2 (fr) 2003-10-29
EP1184458A1 (fr) 2002-03-06
WO2002018948A3 (fr) 2003-08-28
WO2002018948A2 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
US20020115065A1 (en) Differentially expressed epitopes and uses thereof
AU2001294373A1 (en) Differentially expressed epitopes and uses thereof
RU2528738C2 (ru) Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
JP5980202B2 (ja) トランスフェリン受容体を特異的に認識できる抗体
US20220144960A1 (en) Cd30-binding moieties, chimeric antigen receptors, and uses thereof
US20250361321A1 (en) Antibodies to mucin-16 and methods of use thereof
JP7675016B2 (ja) ムチン－１６に対するヒト化抗体およびそれを使用する方法
CN110536901A (zh) 与髓鞘少突胶质细胞糖蛋白结合的抗体
WO2020244526A1 (fr) Anticorps monoclonal anti-ceacam5 et son procédé de préparation et son utilisation
KR101783907B1 (ko) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
WO2022075439A1 (fr) Méthode de détermination de sensibilité ou d'effet médicinal d'un anticorps anti-récepteur de la transferrine
KR102312222B1 (ko) Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체
CN116003603B (zh) 一种cldn18.2抗体及其应用
CN115873111B (zh) 一种cldn18.2抗体及其应用
KR102290335B1 (ko) Cd30을 표적으로 하는 키메라 항원 수용체 및 이의 용도
JP2024012258A (ja) Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体
JP4794303B2 (ja) 固形腫瘍治療剤
CN115975032B (zh) 一种cldn18.2抗体及其应用
EP4613774A1 (fr) Anticorps à domaine unique ciblant ror1 humain
WO2023019393A1 (fr) Anticorps ciblant cd123, récepteurs d'antigènes chimériques et leurs utilisations
WO2025218621A1 (fr) Protéine de liaison à l'antigène ciblant muc1
WO2025099324A1 (fr) Anticorps dirigés contre cd44
EA048637B1 (ru) Антитела против муцина-16 и способы их применения
CN115960229A (zh) 一种cldn18.2抗体及其应用
CN117567617A (zh) 一种cldn18.2抗体及其应用